TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Stroke Canada Optimization of Rehabilitation by Evidence Implementation Trial (SCORE IT)
Brief Summary: The aim of this project is to evaluate whether using an implementation intervention promotes use of best practices by rehabilitation professionals and leads to improvements in patient outcomes for individuals with stroke.


Options:
A: Intervention Type: BEHAVIORAL; Name: Knowledge translation intervention package; Assigned to Arm(s): N/A
B: Arm Label: an intervention arm; Type: EXPERIMENTAL; Interventions: Behavioral: Behaviour Change Wheel model guided intervention | Arm Label: a control arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Behaviour Change Wheel model guided intervention; Assigned to Arm(s): an intervention arm
C: Arm Label: Interprofessional Team Approach; Type: EXPERIMENTAL; Interventions: Other: Interprofessional Team Approach | Arm Label: Usual Home Care Services; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Interprofessional Team Approach; Assigned to Arm(s): Interprofessional Team Approach
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Information feedback | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Information feedback | Intervention Type: BEHAVIORAL; Name: Information feedback; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: Information feedback; Assigned to Arm(s): Arm 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Subacute Trial of Methylphenidate in Parkinson's Disease
Brief Summary: The purpose of this trial is to determine if methylphenidate (MPD), a drug marketed in the U.S. to treat hyperactivity and narcolepsy, added to levodopa, will increase the beneficial effects of levodopa without bothersome side effects in people with Parkinson's disease (PD).


Options:
A: Arm Label: 1mg rasagiline; Type: EXPERIMENTAL; Interventions: Drug: Rasagiline Mesylate | Arm Label: 2mg rasagiline; Type: EXPERIMENTAL; Interventions: Drug: Rasagiline Mesylate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Rasagiline Mesylate; Assigned to Arm(s): 1mg rasagiline | Intervention Type: DRUG; Name: Rasagiline Mesylate; Assigned to Arm(s): 2mg rasagiline | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: pramipexole; Type: EXPERIMENTAL; Interventions: Drug: Pramipexole | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Pramipexole; Assigned to Arm(s): pramipexole | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): placebo
C: Arm Label: occupational therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Occupational Therapy | Arm Label: No occupational therapy; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Occupational Therapy; Assigned to Arm(s): occupational therapy
D: Arm Label: Methylphenidate 0.4 mg/kg TID followed by placebo TID; Type: EXPERIMENTAL; Interventions: Drug: methylphenidate | Arm Label: Placebo TID followed by methylphenidate 0.4 mg/kg TID; Type: EXPERIMENTAL; Interventions: Drug: methylphenidate | Intervention Type: DRUG; Name: methylphenidate; Assigned to Arm(s): Methylphenidate 0.4 mg/kg TID followed by placebo TID, Placebo TID followed by methylphenidate 0.4 mg/kg TID

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vasodilator Therapy and Exercise Tolerance in IPF Patients
Brief Summary: Medicines that decrease blood pressure in the lungs may help idiopathic pulmonary fibrosis (IPF) patients function better. This study will test whether sildenafil improves the ability to exercise in patients with pulmonary fibrosis of unknown cause.


Options:
A: Arm Label: Sildenafil; Type: EXPERIMENTAL; Interventions: Drug: sildenafil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: sildenafil | Intervention Type: DRUG; Name: sildenafil; Assigned to Arm(s): Placebo, Sildenafil
B: Arm Label: Inhaled treprostinil; Type: EXPERIMENTAL; Interventions: Drug: Inhaled treprostinil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo inhalation solution | Intervention Type: DRUG; Name: Inhaled treprostinil; Assigned to Arm(s): Inhaled treprostinil | Intervention Type: DRUG; Name: Placebo inhalation solution; Assigned to Arm(s): Placebo
C: Arm Label: Combination ambrisentan + tadalafil; Type: ACTIVE_COMPARATOR; Interventions: Drug: ambrisentan, Drug: tadalafil | Arm Label: Monotherapy ambrisentan; Type: ACTIVE_COMPARATOR; Interventions: Drug: ambrisentan | Arm Label: Monotherapy tadalafil; Type: ACTIVE_COMPARATOR; Interventions: Drug: tadalafil | Intervention Type: DRUG; Name: ambrisentan; Assigned to Arm(s): Combination ambrisentan + tadalafil, Monotherapy ambrisentan | Intervention Type: DRUG; Name: tadalafil; Assigned to Arm(s): Combination ambrisentan + tadalafil, Monotherapy tadalafil
D: Arm Label: Sildenafil; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sildenafil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sildenafil; Assigned to Arm(s): Sildenafil | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Efficacy and Safety of Silodosin vs. Tamsulosin and Placebo in the Treatment of the Signs and Symptoms of BPH. Multicentre, Randomised, Double-Blind, Controlled Trial With an Optional Long-Term, Open-Label Extension Phase.
Brief Summary: A new drug for the treatment of benign prostatic hyperplasia is compared with placebo and tamsulosin (a drug belonging to the same therapeutic class) for to determine if it is safe and effective (the first phase of the study lasts approximately 18 weeks) and then is used for another 9 months to determine its long-term safety.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo tablet, Drug: Placebo capsule | Arm Label: Tadalafil 5 milligram (mg); Type: EXPERIMENTAL; Interventions: Drug: Tadalafil 5 mg | Arm Label: Tamsulosin 0.4 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tamsulosin | Intervention Type: DRUG; Name: Tadalafil 5 mg; Assigned to Arm(s): Tadalafil 5 milligram (mg) | Intervention Type: DRUG; Name: Placebo tablet; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Tamsulosin; Assigned to Arm(s): Tamsulosin 0.4 mg | Intervention Type: DRUG; Name: Placebo capsule; Assigned to Arm(s): Placebo
B: Arm Label: Silodosin; Type: EXPERIMENTAL; Interventions: Drug: Silodosin | Arm Label: Tamsulosin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tamsulosin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Silodosin; Assigned to Arm(s): Silodosin | Intervention Type: DRUG; Name: Tamsulosin; Assigned to Arm(s): Tamsulosin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Silodosin; Type: EXPERIMENTAL; Interventions: Drug: Silodosin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Silodosin; Assigned to Arm(s): Silodosin | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Silodosin; Type: EXPERIMENTAL; Interventions: Drug: Silodosin | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Silodosin; Assigned to Arm(s): Silodosin | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Long-Term, Open-Label, Multicenter, Extension Study of Bosentan in Patients With Pulmonary Hypertension Associated With Sickle Cell Disease Completing a Double-Blind ASSET Study (AC-052-368 or AC 052-369)
Brief Summary: This study will assess the safety and efficacy of bosentan therapy (in a study known as ASSET) for patients who have high blood pressure in the lungs associated with sickle cell disease. That form of hypertension places people at risk for complications, including shortness of breath, pain, pneumonia, and death. Previous studies have shown that bosentan can be helpful in reducing pulmonary hypertension.

Patients ages 16 and older who have completed the 16-week treatment in the ASSET 1 or ASSET 2 study and who are not pregnant or breastfeeding may be eligible for this study. The research will be conducted in about 25 hospitals in the United States and Europe. Up to 30 participants will be enrolled. The screening visit will involve a physical examination, blood sample of about 3 teaspoons for laboratory tests, and a pregnancy test. Patients' doctors will give them bosentan tablets (62.5 mg each), to take one in the morning and one in the evening. After 1 month, patients will be told whether the dose should be increased to 125 mg tablets to take twice a day. Two weeks after the increase in dose, a blood test will be done to analyze the drug's effects on the liver. After the start of treatment, patients will return for visits every 6 months, when there will be a 6-minute walking test to measure exercise capacity and evaluate shortness of breath. There will be follow-up for patients up to the end of the study and for 28 days after the last dose of bosentan is taken, to collect information about side effects.

Some patients on bosentan have had changes in liver function and red blood cell count. Side effects commonly reported are headache, flushed appearance, inflammation of the throat and nasal passages, and gastrointestinal symptoms. If patients have sudden worsening in breathing in the first few weeks after taking bosentan, they should immediately tell their doctors, because it may be necessary to change the treatment.


Options:
A: Intervention Type: DRUG; Name: bosentan; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: bosentan | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: bosentan; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): N/A
D: Arm Label: Macitentan; Type: EXPERIMENTAL; Interventions: Drug: Macitentan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Macitentan; Assigned to Arm(s): Macitentan | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Health Outcomes for New Mothers and Babies
Brief Summary: Because adherence to postnatal care guidelines across the United States (U.S.) is poor, newborns and mothers often are placed at undue risk for adverse medical and social outcomes. This study aims to evaluate an alternative model of care and improve healthcare delivery to and reduce health disparities for "well" newborns and mothers after hospital discharge by using single postnatal home nurse visits. The principal investigator has previously shown a reduction in poor outcomes for infants who receive a home visit after discharge when studied retrospectively. The proposed research will build on the previous study and prospectively evaluate the impact of a single home nursing visit on morbidities and health disparities for newborns and mothers in a randomized, controlled trial involving 1154 mother/infant breastfeeding dyads. Home visits should guarantee detailed assessment during an at-risk period of infancy and motherhood, where medical and social problems can be recognized, anticipated, and/or treated, and can bridge the gap between hospital care and primary care. The investigators' program, The Nurses for Infants Through Teaching and Assessment after the NurserY (NITTANY) Initiative, also will consider the cost-effectiveness of home visitation compared with guidelines-adherent outpatient clinic care.


Options:
A: Arm Label: Home-based counselling visits by volunteers; Type: EXPERIMENTAL; Interventions: Behavioral: Home-based counselling | Arm Label: Standard care through existing health system; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Home-based counselling; Assigned to Arm(s): Home-based counselling visits by volunteers
B: Intervention Type: BEHAVIORAL; Name: Home Nurse Visit; Assigned to Arm(s): N/A
C: Arm Label: implementation strategy; Type: EXPERIMENTAL; Interventions: Other: implementation strategy of Breastfeeding | Arm Label: Conventional intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: implementation strategy of Breastfeeding; Assigned to Arm(s): implementation strategy
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Low Intensity; Type: OTHER; Interventions: Other: Telephone-based breastfeeding peer counseling | Arm Label: High Intensity; Type: ACTIVE_COMPARATOR; Interventions: Other: Telephone-based breastfeeding peer counseling | Intervention Type: OTHER; Name: Telephone-based breastfeeding peer counseling; Assigned to Arm(s): High Intensity, Low Intensity

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Health Outcomes for New Mothers and Babies
Brief Summary: Because adherence to postnatal care guidelines across the United States (U.S.) is poor, newborns and mothers often are placed at undue risk for adverse medical and social outcomes. This study aims to evaluate an alternative model of care and improve healthcare delivery to and reduce health disparities for "well" newborns and mothers after hospital discharge by using single postnatal home nurse visits. The principal investigator has previously shown a reduction in poor outcomes for infants who receive a home visit after discharge when studied retrospectively. The proposed research will build on the previous study and prospectively evaluate the impact of a single home nursing visit on morbidities and health disparities for newborns and mothers in a randomized, controlled trial involving 1154 mother/infant breastfeeding dyads. Home visits should guarantee detailed assessment during an at-risk period of infancy and motherhood, where medical and social problems can be recognized, anticipated, and/or treated, and can bridge the gap between hospital care and primary care. The investigators' program, The Nurses for Infants Through Teaching and Assessment after the NurserY (NITTANY) Initiative, also will consider the cost-effectiveness of home visitation compared with guidelines-adherent outpatient clinic care.


Options:
A: Arm Label: Lactation Consultant; Type: ACTIVE_COMPARATOR; Interventions: Other: Lactation Consultant support | Arm Label: current treatment for jaundice; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Lactation Consultant support; Assigned to Arm(s): Lactation Consultant
B: Intervention Type: BEHAVIORAL; Name: Home Nurse Visit; Assigned to Arm(s): N/A
C: Arm Label: Standard well child care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Food Activity Breast feeding support; Type: EXPERIMENTAL; Interventions: Behavioral: FAB | Arm Label: Sleep; Type: EXPERIMENTAL; Interventions: Behavioral: Sleep | Arm Label: FAB + Sleep; Type: EXPERIMENTAL; Interventions: Behavioral: FAB, Behavioral: Sleep | Intervention Type: BEHAVIORAL; Name: FAB; Assigned to Arm(s): FAB + Sleep, Food Activity Breast feeding support | Intervention Type: BEHAVIORAL; Name: Sleep; Assigned to Arm(s): FAB + Sleep, Sleep
D: Arm Label: visit with grandmother; Type: EXPERIMENTAL; Interventions: Behavioral: counseling sessions | Arm Label: visit without grandmother; Type: EXPERIMENTAL; Interventions: Behavioral: counseling sessions | Arm Label: no visit with grandmother; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: no visit without grandmother; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: counseling sessions; Assigned to Arm(s): visit with grandmother, visit without grandmother

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Health Outcomes for New Mothers and Babies
Brief Summary: Because adherence to postnatal care guidelines across the United States (U.S.) is poor, newborns and mothers often are placed at undue risk for adverse medical and social outcomes. This study aims to evaluate an alternative model of care and improve healthcare delivery to and reduce health disparities for "well" newborns and mothers after hospital discharge by using single postnatal home nurse visits. The principal investigator has previously shown a reduction in poor outcomes for infants who receive a home visit after discharge when studied retrospectively. The proposed research will build on the previous study and prospectively evaluate the impact of a single home nursing visit on morbidities and health disparities for newborns and mothers in a randomized, controlled trial involving 1154 mother/infant breastfeeding dyads. Home visits should guarantee detailed assessment during an at-risk period of infancy and motherhood, where medical and social problems can be recognized, anticipated, and/or treated, and can bridge the gap between hospital care and primary care. The investigators' program, The Nurses for Infants Through Teaching and Assessment after the NurserY (NITTANY) Initiative, also will consider the cost-effectiveness of home visitation compared with guidelines-adherent outpatient clinic care.


Options:
A: Arm Label: Philani Intervention Program; Type: EXPERIMENTAL; Interventions: Behavioral: Philani Intervention Program | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Philani Intervention Program; Assigned to Arm(s): Philani Intervention Program
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Relaxation; Type: EXPERIMENTAL; Interventions: Behavioral: Relaxation | Intervention Type: BEHAVIORAL; Name: Relaxation; Assigned to Arm(s): Relaxation
C: Arm Label: Nurse-Family Partnership (NFP); Type: EXPERIMENTAL; Interventions: Behavioral: Nurse-Family Partnership (NFP) | Arm Label: Existing services; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Existing services | Intervention Type: BEHAVIORAL; Name: Nurse-Family Partnership (NFP); Assigned to Arm(s): Nurse-Family Partnership (NFP) | Intervention Type: BEHAVIORAL; Name: Existing services; Assigned to Arm(s): Existing services
D: Intervention Type: BEHAVIORAL; Name: Home Nurse Visit; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Health Outcomes for New Mothers and Babies
Brief Summary: Because adherence to postnatal care guidelines across the United States (U.S.) is poor, newborns and mothers often are placed at undue risk for adverse medical and social outcomes. This study aims to evaluate an alternative model of care and improve healthcare delivery to and reduce health disparities for "well" newborns and mothers after hospital discharge by using single postnatal home nurse visits. The principal investigator has previously shown a reduction in poor outcomes for infants who receive a home visit after discharge when studied retrospectively. The proposed research will build on the previous study and prospectively evaluate the impact of a single home nursing visit on morbidities and health disparities for newborns and mothers in a randomized, controlled trial involving 1154 mother/infant breastfeeding dyads. Home visits should guarantee detailed assessment during an at-risk period of infancy and motherhood, where medical and social problems can be recognized, anticipated, and/or treated, and can bridge the gap between hospital care and primary care. The investigators' program, The Nurses for Infants Through Teaching and Assessment after the NurserY (NITTANY) Initiative, also will consider the cost-effectiveness of home visitation compared with guidelines-adherent outpatient clinic care.


Options:
A: Arm Label: 3-week visit; Type: EXPERIMENTAL; Interventions: Other: 3-week visit | Arm Label: usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: usual care | Intervention Type: OTHER; Name: 3-week visit; Assigned to Arm(s): 3-week visit | Intervention Type: OTHER; Name: usual care; Assigned to Arm(s): usual care
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: RLPT | Intervention Type: BEHAVIORAL; Name: RLPT; Assigned to Arm(s): Intervention
C: Arm Label: Postpartum Visit 3-4 Weeks; Type: EXPERIMENTAL; Interventions: Behavioral: Postpartum Visit 3-4 Weeks | Arm Label: Postpartum Visit 6-8 Weeks; Type: EXPERIMENTAL; Interventions: Behavioral: Postpartum Visit 6-8 Weeks | Intervention Type: BEHAVIORAL; Name: Postpartum Visit 3-4 Weeks; Assigned to Arm(s): Postpartum Visit 3-4 Weeks | Intervention Type: BEHAVIORAL; Name: Postpartum Visit 6-8 Weeks; Assigned to Arm(s): Postpartum Visit 6-8 Weeks
D: Intervention Type: BEHAVIORAL; Name: Home Nurse Visit; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Health Outcomes for New Mothers and Babies
Brief Summary: Because adherence to postnatal care guidelines across the United States (U.S.) is poor, newborns and mothers often are placed at undue risk for adverse medical and social outcomes. This study aims to evaluate an alternative model of care and improve healthcare delivery to and reduce health disparities for "well" newborns and mothers after hospital discharge by using single postnatal home nurse visits. The principal investigator has previously shown a reduction in poor outcomes for infants who receive a home visit after discharge when studied retrospectively. The proposed research will build on the previous study and prospectively evaluate the impact of a single home nursing visit on morbidities and health disparities for newborns and mothers in a randomized, controlled trial involving 1154 mother/infant breastfeeding dyads. Home visits should guarantee detailed assessment during an at-risk period of infancy and motherhood, where medical and social problems can be recognized, anticipated, and/or treated, and can bridge the gap between hospital care and primary care. The investigators' program, The Nurses for Infants Through Teaching and Assessment after the NurserY (NITTANY) Initiative, also will consider the cost-effectiveness of home visitation compared with guidelines-adherent outpatient clinic care.


Options:
A: Arm Label: Lactation Consultant; Type: ACTIVE_COMPARATOR; Interventions: Other: Lactation Consultant support | Arm Label: current treatment for jaundice; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Lactation Consultant support; Assigned to Arm(s): Lactation Consultant
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Other: Telephone Support Intervention to Improve Breastfeeding | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Telephone Support Intervention to Improve Breastfeeding; Assigned to Arm(s): A
C: Intervention Type: BEHAVIORAL; Name: Home Nurse Visit; Assigned to Arm(s): N/A
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Breastfeeding promotion and support | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Breastfeeding promotion and support; Assigned to Arm(s): Intervention

Answer: C